Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
|Videos|February 4, 2022
Pharmaceutical Executive Roundtable: Future Shaping in Sales and Marketing: Preventative Medicine, Population Health, and Branding
In this segment, members of the panel discuss how to make medicine more accessible to the broader population. And how does the industry address affordability?
Advertisement
Advertisement
Related to this article
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Fox Rothschild's Marc Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
3
The Manufacturing Issues That Continue to Contribute to Drug Shortages
4
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeutics Enters Collaboration and License Agreement to Develop Sec61-Targeting Small Molecules
5